Amylyx Pharmaceuticals, Inc. (AMLX)
- Sector
- Pharmaceuticals
- Last price
- $28.07
- As of
Kresmion compiles this page from AMLX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Amylyx Pharmaceuticals, Inc. (AMLX): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.
See the full AMLX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AMLX on one page. Preview it with sample data, then open it live with a free account.
Preview the AMLX dossierActive events for AMLX
- high13F: funds added
4 tracked funds increased AMLX this 2026Q2, institutional consensus
- mediumEarnings below estimates
Q2-2026: Missed consensus by 5.9%, EPS $-0.39 vs $-0.3681 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +1766% to AMLX (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 93% of AMLX (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 92% of AMLX (2026Q2)
FREE, NO ACCOUNT
Every event on AMLX, as it fires
You are seeing 5 of 13 events recorded on AMLX since 2026-05-16.
The five above landed across 3 days. The other 8 were recorded on 3 other days. 7 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AMLX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 03237H101 · 2026Q2 | $10.7M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 03237H101 · 2026Q2 | $3.2M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 03237H101 · 2026Q2 | $3.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AMLX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AMLX against its peers
AMLX's return on equity of -47.4% ranks in the 25th percentile of 21 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | AMLX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 719M USD | 2 | 21 |
| Gross margin | n/a | 76.0% | n/a | 10 |
| Operating margin | n/a | 4.3% | n/a | 20 |
| Net margin | n/a | 0.2% | n/a | 21 |
| Return on equity | -47.4% | -8.2% | 25 | 21 |
| P / E | n/a | 17.8x | n/a | 10 |
Peers (25): OGN, TARS, LQDA, BHC, SUPN, HRMY, XERS, TRVI, AMRX, AXSM, ANIP, NUVB, OCUL, PAHC, GPCR, INVA, PCRX, CORT, NKTR, OMER, AMPH, ANRO, JAZZ, ALMS, ESPR.D. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (AMLX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow AMLX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to AMLX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.